EGFR突变肺腺癌 TKI 后小细胞转化：RB1/TP53 风险

类型: 论文 发表日期: 2025-05-06 入库日期: 2026-05-21 来源: PubMed 标签: EGFR L858R, RB1, TP53, NSE, 小细胞转化, 再活检

Citation

Molecular mechanisms and therapeutic strategies for small-cell lung cancer transformation after TKI therapy in EGFR-mutated lung adenocarcinoma (Review). PubMed: 40384936

Related case-review signal: Potential therapeutic option for EGFR-mutant small cell lung cancer transformation

Why this is in CCL

Mom’s baseline multigene panel shows RB1 frameshift alteration and TP53 mutation. Her NSE rose sharply in March 2026. That combination makes SCLC transformation a specific watch item, not just a generic resistance concern.

Key takeaways

• Reviews describe RB1 and TP53 loss/alteration as recurrent biology associated with SCLC transformation after EGFR TKI therapy.
• Rising neuroendocrine markers such as NSE can be a clue, but tissue confirmation is needed.
• Transformation changes treatment logic; small-cell-like regimens such as platinum/etoposide may enter the discussion if confirmed.

Practical relevance

• If progression is suspected, prioritize biopsy of an accessible progressing lesion and request histology plus neuroendocrine IHC and NGS.
• Do not assume SCLC transformation from NSE alone; treat it as a trigger for diagnostic confirmation.